Top 10 Companies in the (S)-Ethyl 2‑amino‑2‑phenylacetate Hydrochloride (CAS 17609‑48‑2) Market (2026): Market Leaders Powering Global Pharmaceutical Supply

MARKET INSIGHTS

Global (S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride (CAS 17609‑48‑2) market size was valued at USD 28.4 million in 2025. The market is projected to rise from USD 30.1 million in 2026 to USD 52.7 million by 2034, reflecting a 7.3% compound annual growth rate during the forecast period.

(S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride is a chiral amino acid ester derivative that plays a pivotal role in the synthesis of optically active compounds. With the molecular formula C₁₀H₁₄ClNO₂, it functions as a key building block in asymmetric synthesis, especially for active pharmaceutical ingredients (APIs) that demand high enantiomeric purity. Its hydrochloride salt form delivers enhanced stability and simplifies handling in both laboratory and industrial settings.

The expanding pharmaceutical and fine‑chemical sectors, coupled with a rising appetite for enantiopure intermediates, are driving market momentum. Investment in chiral chemistry and the adoption of stereoselective synthesis processes further accelerate growth. Leading specialty chemical manufacturers and pharmaceutical ingredient suppliers across North America, Europe, and Asia‑Pacific are actively expanding their chiral compound portfolios to satisfy evolving industry needs.

(S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride (CAS 17609‑48‑2) Market – View in Detailed Research Report

Top 10 Companies in the Market

1. Hairui Chemical Co., Ltd. (China)

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical‑grade chiral intermediates

Hairui Chemical has built a robust production line that consistently delivers >99% optical purity. Its focus on cGMP compliance has positioned the company as a trusted supplier for large‑scale antibiotic production. The firm’s recent expansion into continuous flow synthesis has cut batch times by 30%, offering a competitive edge in cost and throughput.

Sustainability & Growth Initiatives: Hairui is investing in green catalysis to reduce solvent use and has achieved a 15% reduction in carbon footprint across its facilities.

Investment in renewable energy for manufacturing plants
Partnerships with leading CDMOs for joint development projects
Launch of a new high‑purity API platform in 2025

2. Capot Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Technical‑grade chiral intermediates

Capot Chemical’s expertise lies in enzymatic resolution techniques that deliver ultra‑high purity products. The company’s focus on process efficiency has allowed it to maintain competitive pricing while meeting stringent regulatory requirements.

Sustainability & Growth Initiatives: Capot has implemented a closed‑loop waste management system, achieving zero liquid discharge in 2024.

Expansion of production capacity by 25% in 2025
Collaboration with academic institutions on chiral catalyst research
Development of a digital supply‑chain platform for real‑time inventory tracking

3. Finetech Industry Limited (China)

Headquarters: Shenzhen, China
Key Offering: Research‑grade chiral reagents

Finetech focuses on delivering high‑purity reagents for R&D laboratories. Its portfolio includes a range of chiral building blocks that support the development of next‑generation antibiotics and peptide therapeutics.

Sustainability & Growth Initiatives: The company has adopted a zero‑waste policy for its research facilities.

Launch of a new biocatalytic platform in 2025
Strategic alliance with a leading CRO to offer custom synthesis services
Investment in AI‑driven process optimization tools

4. Shanghai Trustin Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: High‑purity chiral intermediates

Shanghai Trustin has carved out a niche in producing chiral intermediates with impurity profiles below ICH limits. Its rigorous quality control framework ensures consistent delivery for global pharmaceutical clients.

Sustainability & Growth Initiatives: Trustin has reduced solvent usage by 20% through process intensification.

Expansion of the Shanghai facility by 30% in 2026
Collaboration with a leading university on enzyme engineering
Implementation of a digital twin for production line monitoring

5. Beijing Lunyao Tiangong Science and Technology Co., Ltd. (China)

Headquarters: Beijing, China
Key Offering: Technical‑grade chiral intermediates

Beijing Lunyao Tiangong specializes in the synthesis of chiral intermediates for both pharmaceutical and agrochemical markets. Its emphasis on process scalability has attracted several multinational clients.

Sustainability & Growth Initiatives: The company has achieved a 10% reduction in water consumption through advanced recycling systems.

Launch of a new product line targeting beta‑lactam antibiotics in 2025
Strategic partnership with a European CDMO for joint development
Adoption of blockchain for traceability in the supply chain

6. Hangzhou Dayangchem Co. Ltd. (China)

Headquarters: Hangzhou, China
Key Offering: Pharmaceutical‑grade chiral intermediates

Dayangchem’s production processes are engineered for high throughput and strict impurity control, making it a preferred supplier for large‑scale API manufacturing.

Sustainability & Growth Initiatives: The firm has integrated renewable energy sources into its operations, cutting greenhouse gas emissions by 12%.

Expansion of the Hangzhou plant by 20% in 2026
Collaboration with a leading CRO for custom synthesis services
Implementation of a real‑time quality monitoring system

7. Ningbo Inno Pharmchem Co., Ltd. (China)

Headquarters: Ningbo, China
Key Offering: Research‑grade chiral reagents

Inno Pharmchem focuses on providing high‑purity reagents for academic and industrial research. Its portfolio supports the development of novel chiral molecules for drug discovery.

Sustainability & Growth Initiatives: The company has adopted a circular economy model for its chemical waste streams.

Launch of a new enzymatic resolution platform in 2025
Strategic alliance with a biotech firm for joint R&D
Investment in AI‑driven synthesis planning tools

8. Taizhou Crene Biotechnology Co., Ltd. (China)

Headquarters: Taizhou, China
Key Offering: Technical‑grade chiral intermediates

Crene Biotechnology specializes in the synthesis of chiral intermediates for peptide therapeutics. Its production lines are designed for flexibility, allowing rapid scale‑up for emerging drug candidates.

Sustainability & Growth Initiatives: The firm has implemented a zero‑waste policy for its peptide synthesis processes.

Expansion of the Taizhou facility by 15% in 2026
Collaboration with a leading peptide manufacturer for joint development
Adoption of green chemistry principles across all production lines

9. Qingdao Fengchen Technology and Trade (China)

Headquarters: Qingdao, China
Key Offering: Pharmaceutical‑grade chiral intermediates

Fengchen Technology focuses on delivering high‑purity chiral intermediates for antibiotic and peptide synthesis. Its emphasis on process efficiency and regulatory compliance has earned it a strong reputation in the global market.

Sustainability & Growth Initiatives: The company has reduced energy consumption by 18% through process optimization.

Launch of a new continuous flow synthesis line in 2025
Strategic partnership with a global CDMO for custom synthesis
Implementation of a digital platform for supply‑chain transparency

10. Amino Chemicals Ltd. (Canada)

Headquarters: Toronto, Canada
Key Offering: High‑purity chiral intermediates

Amino Chemicals brings a strong focus on regulatory compliance and quality control, catering to the North American market. Its portfolio includes chiral intermediates for antibiotics and other APIs.

Sustainability & Growth Initiatives: The firm has adopted renewable energy for its Canadian operations, achieving 100% clean electricity usage.

Expansion of the Toronto facility by 10% in 2026
Collaboration with a leading Canadian university on chiral catalyst research
Implementation of a real‑time quality monitoring system

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/307887/ethyl-aminophenylacetate-hydrochloride-market

Get Full Report: https://www.24chemicalresearch.com/reports/307887/ethyl-aminophenylacetate-hydrochloride-market

Outlook

Over the next decade, the (S)-Ethyl 2‑amino‑2‑phenylacetate hydrochloride market is expected to maintain a steady expansion trajectory. The convergence of increasing demand for high‑purity intermediates, regulatory emphasis on enantiomeric purity, and the growth of generic drug production will sustain the upward trend. Market players that invest in continuous flow technologies and green chemistry are likely to capture higher market shares, while those that lag behind may face margin pressures.

Future Trends

Key future developments include:

Adoption of biocatalytic and enzymatic resolution methods to lower energy consumption and reduce waste.
Integration of digital platforms for real‑time quality monitoring and supply‑chain transparency.
Expansion of the chiral intermediate portfolio to support peptide therapeutics and other emerging drug classes.
Strategic collaborations between fine‑chemical manufacturers and CDMOs to accelerate product development timelines.

Author
Recent Posts

Rohit k